FLT3 and acute myeloid leukemia: The therapeutic landscape in AML has been greatly expanded the last few years after decades of stagnation, with the regulatory agencies approving eight new therapies, including improvements in chemotherapy, inhibitors of FMS-related receptor tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase (IDH), and drugs targeting BCL-2 and the Hedgehog signaling pathway [3].